SCHEMBL24348485

SCHEMBL24348485

Cc1nc(COCC(=O)O)sc1-c1csc(-c2cc(F)c(O)c(F)c2F)n1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 5/20 0.69
▸ KMT2A Q03164 2/20 0.37
▸ PPARD Q03181 9/20 0.36
▸ FFAR1 O14842 6/20 0.33
▸ PIK3CD O00329 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ PI4KB Q9UBF8 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PIK3CG P48736 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24349243 0.91 BPGM (0.67) BPGMKMT2APPARDPIK3CDPIK3CA
SCHEMBL24348968 0.87 BPGM (0.62) BPGMPIK3CDPIK3CAMAPTHPGD
SCHEMBL24349009 0.85 BPGM (0.60) BPGMKMT2APIK3CDPIK3CAMAPT
SCHEMBL24348500 0.85 BPGM (0.60) BPGMPIK3CDPIK3CA
SCHEMBL24348057 0.85 BPGM (0.69) BPGMKMT2APIK3CDPIK3CAMAPT
SCHEMBL24348043 0.84 BPGM (0.59) BPGMPIK3CDPIK3CA
SCHEMBL30634054 0.83 BPGM (0.48) BPGMKMT2APPARDMEN1GAA
SCHEMBL24271976 0.83 BPGM (0.48) BPGMKMT2APPARDMEN1GAA
SCHEMBL24348039 0.82 BPGM (0.71) BPGMKMT2APIK3CDPIK3CAMAPT
SCHEMBL24348497 0.82 BPGM (0.66) BPGMKMT2APIK3CDPIK3CAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885KMT2A 2844/4885PPARD 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback